Bristol Myers Squibb Files 8-K

TL;DR

BMS filed an 8-K on Nov 10 for Oct 31 events. Details pending.

AI Summary

Bristol Myers Squibb Company filed an 8-K on November 10, 2025, reporting events as of October 31, 2025. The filing includes information on "Other Events" and "Financial Statements and Exhibits." Specific details regarding the nature of these events or financial statements are not elaborated in the provided text.

Why It Matters

This filing indicates Bristol Myers Squibb is providing updated information to the SEC, which could pertain to significant corporate events or financial disclosures.

Risk Assessment

Risk Level: low — The filing is a routine disclosure and does not appear to contain immediate negative news.

Key Players & Entities

• BRISTOL MYERS SQUIBB COMPANY (company) — Filer
• November 10, 2025 (date) — Filing Date
• October 31, 2025 (date) — Report Date
• 0000014272 (company) — Central Index Key
• 22-0790350 (company) — EIN

FAQ

Key Financial Figures

• $0.10 — ange on which registered Common Stock, $0.10 Par Value BMY New York Stock Exchan
• $3.0 billion — e Offering, together with approximately $3.0 billion of cash on hand, (i) to fund the Compan

Filing Documents

• ny20057651x6_8k.htm (8-K) — 55KB
• ny20057651x6_ex1-1.htm (EX-1.1) — 362KB
• ny20057651x6_ex4-2.htm (EX-4.2) — 423KB
• ny20057651x6_ex5-1.htm (EX-5.1) — 32KB
• ny20057651x6_ex5-2.htm (EX-5.2) — 59KB
• ny20057651x6_ex5-1img1.jpg (GRAPHIC) — 53KB
• ny20057651x6_ex5-1img2.jpg (GRAPHIC) — 103KB
• ny20057651x6_ex5-2img1.jpg (GRAPHIC) — 69KB
• ny20057651x6_ex5-2img2.jpg (GRAPHIC) — 349KB
• ny20057651x6_ex5-2img3.jpg (GRAPHIC) — 15KB
• 0001140361-25-041380.txt ( ) — 2059KB
• bmy-20251031.xsd (EX-101.SCH) — 4KB
• bmy-20251031_def.xml (EX-101.DEF) — 18KB
• bmy-20251031_lab.xml (EX-101.LAB) — 26KB
• bmy-20251031_pre.xml (EX-101.PRE) — 20KB
• ny20057651x6_8k_htm.xml (XML) — 7KB

01

Item 8.01. Other Events. Indenture On November 10, 2025, BMS Ireland Capital Funding Designated Activity Company (the "Issuer"), a designated activity company incorporated under the laws of Ireland and a wholly-owned subsidiary of Bristol-Myers Squibb Company (the "Company"), completed the public offering (the "Offering") of (i) 750,000,000 aggregate principal amount of 2.973% Notes due 2030 (the "2030 Notes"), (ii) 1,150,000,000 aggregate principal amount of 3.363% Notes due 2033 (the "2033 Notes"), (iii) 1,150,000,000 aggregate principal amount of 3.857% Notes due 2038 (the "2038 Notes"), (iv) 750,000,000 aggregate principal amount of 4.289% Notes due 2045 (the "2045 Notes") and (v) 1,200,000,000 aggregate principal amount of 4.581% Notes due 2055 (the "2055 Notes" and, together with the 2030 Notes, the 2033 Notes, the 2038 and the 2045 Notes, collectively, the "Notes"). The Notes are fully and unconditionally guaranteed on a senior unsecured basis by the Company (collectively, the "Guarantee"). The Notes are governed by and were issued pursuant to that certain Indenture (the "Base Indenture"), dated as of October 31, 2025, among the Issuer, the Company and The Bank of New York Mellon, as trustee (the "Trustee"), as supplemented by the First Supplemental Indenture (the "First Supplemental Indenture" and, the Base Indenture as so supplemented, the "Indenture"), dated as of November 10, 2025, among the Issuer, the Company and the Trustee. The Indenture contains customary covenants and restrictions, including covenants that require the Issuer to satisfy certain conditions in order to incur debt secured by liens, engage in sale/leaseback transactions or merge or consolidate with another entity. The Indenture also provides for customary events of default. The Company intends to use the net proceeds of the Offering, together with approximately $3.0 billion of cash on hand, (i) to fund the Company's tender offer to purchase, for cash, various series of the Company'

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits The following exhibits are included as part of this Current Report: Exhibit No. Description 1.1 Underwriting Agreement, dated November 5, 2025, among BMS Ireland Capital Funding Designated Activity Company, Bristol-Myers Squibb Company and the underwriters named therein. 4.1 Indenture, dated as of October 31, 2025, by and among BMS Ireland Capital Funding Designated Activity Company, Bristol-Myers Squibb Company and The Bank of New York Mellon, as Trustee (incorporated by reference to Exhibit 4c to the Post-Effective Amendment No. 1 to the Registration Statement on Form S-3 (Registration Nos. 333-283810 and 333-283810-01)). 4.2 First Supplemental Indenture, dated as of November 10, 2025, by and among BMS Ireland Capital Funding Designated Activity Company, Bristol-Myers Squibb Company and The Bank of New York Mellon, as Trustee, to the Indenture dated as of October 31, 2025. 4.3 Form of 750,000,000 2.973% Notes due 2030 (included as Exhibit A to Exhibit 4.2). 4.4 Form of 1,150,000,000 3.363% Notes due 2033 (included as Exhibit B to Exhibit 4.2). 4.5 Form of 1,150,000,000 3.857% Notes due 2038 (included as Exhibit C to Exhibit 4.2). 4.6 Form of 750,000,000 4.289% Notes due 2045 (included as Exhibit D to Exhibit 4.2). 4.7 Form of 1,200,000,000 4.581% Notes due 2055 (included as Exhibit E to Exhibit 4.2). 5.1 Opinion of Kirkland & Ellis LLP. 5.2 Opinion of Arthur Cox LLP. 23.1 Consent of Kirkland & Ellis LLP (included in Exhibit 5.1 of this Current Report on Form 8-K). 23.2 Consent of Arthur Cox LLP (included in Exhibit 5.2 of this Current Report on Form 8-K). 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRISTOL-MYERS SQUIBB COMPANY Dated: November 10, 2025 By: /s/ Amy Fallone Name: Amy Fallone Title: Senior Vice President and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR